copper histidinate
Orphan Drug Cold Chain RequiredFDA Approved (Orphan)
Description
Copper histidinate is a parenteral copper replacement therapy used in Menkes disease, a rare X-linked disorder of copper metabolism. Early treatment with subcutaneous copper injections can improve neurological outcomes if initiated in the first weeks of life. The therapy aims to bypass the defective ATP7A copper transporter.
Indications & Therapeutic Use
Menkes disease, copper deficiency
Linked Diseases:
Menkes disease
E83.0D007706
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
copper histidinate
| Generic Name | copper histidinate |
| Active Ingredient | copper histidinate |
| Drug Class | Menkes disease |
| Manufacturer | Various |
| Dosage Forms | Subcutaneous injection, 250 mcg/mL |
| Medical Code | A12CX |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved (Orphan) |
| Clinical Trial | NCT00001272 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes